Andere talen Keros Therapeutics, Inc.

Aandelen

KROS

US4923271013

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
58,62 ^USD	+1,31%		+5,09%	+47,43%

19/03	Morphic Holding benoemt Simon Cooper als Chief Medical Officer	MT
15/03	Aandelen Keros Therapeutics stijgen na FDA Fast Track-aanwijzing voor potentieel geneesmiddel tegen bloedarmoede	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Morphic Holding Names Simon Cooper as Chief Medical Officer	19/03
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug	15/03
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug	14/03
Keros Gets FDA Fast-Track Designation for Lead Drug KER-050	14/03
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	14/03
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	14/03
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference	05/03
Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024	05/03
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	28/02
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q4 Revenue $143,000	28/02
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress	29/01
Adipositas-Mittel führen zu Muskelverlust - Pharmafirmen steuern gegen	22/01
Keros Therapeutics Closes $151.3 Million Stock Offering	09/01
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock	09/01
Keros Therapeutics Prices Stock Offering at $40 a Share	04/01
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock	04/01
Keros Therapeutics Proposes $120 Million Common Stock Offering	03/01
Keros Therapeutics Announces Proposed Public Offering of Common Stock	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Keros Therapeutics, Inc.

Aandelen

KROS

US4923271013

Andere talen

Filters